ArticleAAPS PharmSciTech2025
Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineered membrane-coated nanoparticles enhance ferroptosis and microtubule inhibition in prostate cancer.Journal of materials science. Materials in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cabazitaxel (CTX) is primarily used in the clinical treatment of prostate cancer. The clinical CTX injection (Jevtana®) contains the solubilizer Tween 80, which can lead to serious toxic side effects during intravenous injection. This study developed a novel nanodelivery system for encapsulating CTX, eliminating the need for Tween 80 and addressing current clinical challenges associated with CTX use. The nanodelivery system uses the hydrophilic polymer polyvinylpyrrolidone K12 (PVP K12) as a dispersing agent and a small amount of highly biocompatible sodium cholesteryl sulfate (SCS) as a stabilizer, forming a cabazitaxel nanodispersion (CTX-NP) through the water dispersion method. The CTX-NP exhibited a spherical shape, uniform distribution, a particle size of 128.90 ± 0.42 nm, a PDI of 0.14 ± 0.01, a zeta potential of -65.88 ± 1.23 mV, and a drug encapsulation efficiency of 97.58 ± 0.58%. Furthermore, hemolysis, vascular irritation, and maximum tolerated dose (MTD) experiments indicated that CTX-NP has good biocompatibility compared to cabazitaxel-Tween injection (CTX-TW). The pharmacokinetic studies in rats revealed that, compared to CTX-TW, CTX-NP had an extended half-life (T
Indexed as
Identifiers
41350954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.